In:
British Journal of Haematology, Wiley, Vol. 175, No. 3 ( 2016-11), p. 410-418
Kurzfassung:
In recent decades, the prognosis of Mantle Cell Lymphoma ( MCL ) has been significantly improved by intensified first‐line regimens containing cytarabine, rituximab and consolidation with high‐dose‐therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL 2 regimen, developed by the Nordic Lymphoma Group. We here present the 15‐year updated results of the Nordic MCL 2 study after a median follow‐up of 11·4 years: For all patients on an intent‐to‐treat basis, the median overall and progression‐free survival was 12·7 and 8·5 years, respectively. The MCL International Prognostic Index ( MIPI ), biological MIPI , including Ki67 expression ( MIPI ‐B) and the MIPI ‐B including mIR ‐18b expression ( MIPI ‐B‐miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12 years, we still see an excess disease‐related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL .
Materialart:
Online-Ressource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2016.175.issue-3
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
1475751-5
